Livnat Brill1, Esther Ganelin-Cohen2, Ron Dabby3, Shira Rabinowicz4, Efrat Zohar-Dayan4, Netaniel Rein1, Eyal Aloni5, Yuval Karmon6, Adi Vaknin-Dembinsky1. 1. Department of Neurology and Laboratory of Neuroimmunology, The Agnes Ginges Center for Neurogenetics, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. 2. Schneider Children's Medical Center, Institute of Pediatric Neurology, Affiliated With Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Department of Neurology, Edith Wolfson Medical Center, Holon, Affiliated With Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. 4. Pediatric Neurology Unit, Sheba Medical Center, Ramat Gan, Israel. Sackler School of Medicine, The Edmond and Lilly Safra Children's Hospital, Tel-Aviv University, Tel-Aviv, Israel. 5. Department of Ophthalmology, Barzilai University Medical Center, Ashkelon, Israel. 6. Department of Neurology, Meir General Hospital, Kfar Saba, Israel.
Abstract
Introduction: Myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD) have been recognized over the past 10 years as distinct inflammatory, demyelinating diseases of the central nervous system (CNS). Antibodies against MOG are found mostly in patients with optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and aquaporin-4 antibody (AQP4-abs)-seronegative neuromyelitis optica spectrum disorders (NMOSD). However, data on the disease course and disability outcomes of these patients are scarce. Aim: To describe clinical and paraclinical features associated with MOG antibodies (abs) in a cohort of patients in Israel, and to assess baseline prognostic features of MOG-ab-associated diseases after a first acute demyelinating event. Methods: MOG-abs were identified in serum using a cell-based assay, and clinical data were collected from the patients' medical records. Results: Of 683 patients with demyelinating diseases tested for MOG-abs, 53 were positive (7.7%), with ON the most common presenting phenotype (68%). The age range of MOG-abs seropositive patients was 1-66 years, with increased prevalence in children (19% compared to 6.7% in adults) (p < 0.01). The highest prevalence of seropositivity was observed in children aged younger than 10 years (25.5%), followed by those aged 31-40 years (16.6%). Conclusions: MOGAD are distinct autoimmune diseases that occurs at all stages of life with a significantly higher prevalence in children; the main clinical presenting phenotype in the entire cohort is ON and young children most often presented with ON or ADEM. Our data highlight the need for repeated evaluation of MOG-abs in patients with acquired CNS demyelinating disorders, especially in children under 10 and adults between 31 and 40 years of age.
Introduction: Myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD) have been recognized over the past 10 years as distinct inflammatory, demyelinating diseases of the central nervous system (CNS). Antibodies against MOG are found mostly in patients with optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and aquaporin-4 antibody (AQP4-abs)-seronegative neuromyelitis optica spectrum disorders (NMOSD). However, data on the disease course and disability outcomes of these patients are scarce. Aim: To describe clinical and paraclinical features associated with MOG antibodies (abs) in a cohort of patients in Israel, and to assess baseline prognostic features of MOG-ab-associated diseases after a first acute demyelinating event. Methods:MOG-abs were identified in serum using a cell-based assay, and clinical data were collected from the patients' medical records. Results: Of 683 patients with demyelinating diseases tested for MOG-abs, 53 were positive (7.7%), with ON the most common presenting phenotype (68%). The age range of MOG-abs seropositive patients was 1-66 years, with increased prevalence in children (19% compared to 6.7% in adults) (p < 0.01). The highest prevalence of seropositivity was observed in children aged younger than 10 years (25.5%), followed by those aged 31-40 years (16.6%). Conclusions: MOGAD are distinct autoimmune diseases that occurs at all stages of life with a significantly higher prevalence in children; the main clinical presenting phenotype in the entire cohort is ON and young children most often presented with ON or ADEM. Our data highlight the need for repeated evaluation of MOG-abs in patients with acquired CNS demyelinating disorders, especially in children under 10 and adults between 31 and 40 years of age.
Authors: Maria Sepúlveda; Marta Aldea; Domingo Escudero; Sara Llufriu; Georgina Arrambide; Susana Otero-Romero; J Sastre-Garriga; Lucía Romero-Pinel; Sergio Martínez-Yélamos; N Sola-Valls; Thais Armangué; Javier Sotoca; Antonio Escartín; René Robles-Cedeño; Lluís Ramió-Torrentà; Silvia Presas-Rodríguez; Cristina Ramo-Tello; Elvira Munteis; Raúl Pelayo; Laura Gubieras; Luis Brieva; Nicolau Ortiz; Mariona Hervás; Maria Alba Mañé-Martínez; Antonio Cano; Emili Vela; Mar Tintoré; Yolanda Blanco; Xavier Montalban; Francesc Graus; Albert Saiz Journal: Mult Scler Date: 2017-10-06 Impact factor: 6.312
Authors: L Pandit; N Asgari; M Apiwattanakul; J Palace; F Paul; M I Leite; I Kleiter; T Chitnis Journal: Mult Scler Date: 2015-04-28 Impact factor: 6.312
Authors: Andreas Wegener-Panzer; Robert Cleaveland; Eva-Maria Wendel; Matthias Baumann; Annikki Bertolini; Martin Häusler; Ellen Knierim; Edith Reiter-Fink; Markus Breu; Özcan Sönmez; Adela Della Marina; Renate Peters; Christian Lechner; Martin Piepkorn; Claudia Roll; Romana Höftberger; Frank Leypoldt; Markus Reindl; Kevin Rostásy Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-05-01
Authors: C L de Mol; Yym Wong; E D van Pelt; Bha Wokke; Tam Siepman; R F Neuteboom; D Hamann; R Q Hintzen Journal: Mult Scler Date: 2019-05-16 Impact factor: 6.312
Authors: Markus Reindl; Kathrin Schanda; Mark Woodhall; Fiona Tea; Sudarshini Ramanathan; Jessica Sagen; James P Fryer; John Mills; Bianca Teegen; Swantje Mindorf; Nora Ritter; Ulrike Krummrei; Winfried Stöcker; Juliane Eggert; Eoin P Flanagan; Melanie Ramberger; Harald Hegen; Kevin Rostasy; Thomas Berger; Maria Isabel Leite; Jacqueline Palace; Sarosh R Irani; Russell C Dale; Christian Probst; Monika Probst; Fabienne Brilot; Sean J Pittock; Patrick Waters Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-02-05
Authors: Ki Hoon Kim; Su-Hyun Kim; Jae-Won Hyun; Yeseul Kim; Hyewon Park; Ho Jin Kim Journal: Ann Clin Transl Neurol Date: 2022-08-06 Impact factor: 5.430